Nobilis Rismavac + CA126

Ülke: İrlanda

Dil: İngilizce

Kaynak: HPRA (Health Products Regulatory Authority)

Aktif bileşen:

Live chicken herpes virus strain CVI-988; Live turkey herpes virus strain FC126

Mevcut itibaren:

Intervet Ireland Limited

ATC kodu:

QI01AD03

INN (International Adı):

Live chicken herpes virus strain CVI-988; Live turkey herpes virus strain FC126

Doz:

3.0 log10 - 4.1 log10 plaque forming unit

Farmasötik formu:

Concentrate for solution for injection

Reçete türü:

POM: Prescription Only Medicine as defined in relevant national legislation

Terapötik grubu:

Chickens

Terapötik alanı:

avian herpes virus (marek's disease)

Terapötik endikasyonlar:

Immunological - Live Vaccine

Yetkilendirme durumu:

Authorised

Yetkilendirme tarihi:

2003-08-06

Ürün özellikleri

Proprietary
SUMMARY OF PRODUCT
CHARACTERISTICS
1
NAME OF THE VETERINARY MEDICINAL PRODUCT
Nobilis Rismavac + CA126
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE
PER DOSE
Live Turkey Herpes virus strain
FC126
> 3.0 log
10
pfu*
Live Chicken Herpes virus
strain CVI-988
> 3.0 log
10
pfu
EXCIPIENTS
For a full list of excipients, see section 6.1
* pfu = plaque forming units in chicken embryo fibroblasts
3
PHARMACEUTICAL FORM
Concentrate for solution for injection.
4
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Chickens
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the active immunisation of 18-day embryonated eggs or day-old
chickens to reduce
mortality, clinical signs and lesions after infection with Marek’s
Disease virus.
Duration of immunity is unknown
.
4.3
CONTRAINDICATIONS
None
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
A good immune response is reliant on the reaction of an immunogenic
agent and a fully competent
immune system. Immunogenicity of the vaccine antigen will be reduced
by poor storage or
inappropriate administration. Immuno-competence of the animal may be
compromised by a variety of
factors including poor health, nutritional status, genetic factors,
concurrent drug therapy and stress.
Under certain conditions, for example extreme disease pressure, fully
immune birds may succumb to
disease. Therefore, successful vaccination may not be synonymous with
full protection in the face of a
disease challenge.
Proprietary
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Do not use in unhealthy birds. Sick or weak birds will not develop
adequate immunity
following vaccination. The vaccine viruses spread; care should be
taken to prevent
such spread in multi-age sites.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY MEDICINAL
PRODUCT TO ANIMALS
The operator should be aware of the general precautions to be taken
when handling liquid
nitrogen and/or material at very low temperature. Ampoules may explode
on sudden
temperature changes, therefo